In the growing debate over prescription drug prices in the United States, two competing approaches have emerged — one rooted in political dealmaking and the other in structured government policy. As attention turns to upcoming Medicare drug price negotiations, the tension between short-term agreements and long-term reform is becoming increasingly visible.
Former President Donald Trump has recently highlighted a series of new deals with pharmaceutical companies aimed at reducing the cost of popular weight loss and diabetes medications, such as Wegovy and Zepbound. These voluntary agreements, he claims, will help make treatments more accessible to Americans. However, while these announcements have generated significant media attention, Trump has said little about a government-led effort expected to have a far broader and more lasting impact — the Medicare drug price negotiation program, introduced under President Joe Biden’s Inflation Reduction Act of 2022.
The program grants Medicare the power to negotiate directly with drug manufacturers on some of the country’s most expensive medications, aiming to bring sustainable relief to millions of older adults. According to the Centers for Medicare and Medicaid Services (CMS), the second round of negotiated prices is set to be released by the end of November, covering 15 prescription drugs — including Ozempic and Wegovy — compared with 10 in the previous cycle. Although the new rates will not take effect until 2027, experts believe this process represents one of the most consequential steps toward lowering drug costs in U.S. history.
Differing perspectives on pharmaceutical cost restructuring
The contrast between Trump’s approach and the structured Medicare negotiation process has drawn attention from health policy experts. Trump’s strategy leans heavily on executive actions and voluntary deals with pharmaceutical companies rather than on legislative frameworks. His administration recently reached agreements with Novo Nordisk and Eli Lilly, the companies behind Wegovy and Zepbound, to reduce prices on certain doses. In exchange, the deals reportedly include tariff relief and faster Food and Drug Administration (FDA) review for new drugs — though details remain vague.
Critics contend that these types of agreements might yield immediate political wins instead of enduring resolutions. “These impromptu discussions seem to favor public declarations over fundamental reform,” stated Dr. Benjamin Rome, a health policy expert at Harvard Medical School. Rome highlighted that although reducing medication costs via executive decree could provide instant recognition, it lacks the foresight and responsibility inherent in the Medicare negotiation structure.
The voluntary agreements, though possibly advantageous for certain medications, also provoke concerns regarding openness and uniformity. In the absence of explicit supervision or official cost-management frameworks, specialists are still unsure if these will result in substantial financial relief for patients. Conversely, the Medicare negotiation initiative establishes a lawful and replicable procedure designed to progressively reduce expenses for an expanding catalog of pharmaceuticals.
The significance of Medicare’s negotiation authority
The Inflation Reduction Act marked a historic shift by giving Medicare — the nation’s largest buyer of prescription drugs — the authority to bargain directly with manufacturers. Before its passage, the federal government was barred from negotiating prices, leaving pharmaceutical companies free to set rates largely unchecked.
The first round of negotiations, announced in 2024, targeted ten high-cost drugs, including the blood thinner Eliquis and several treatments for cancer and diabetes. These initial agreements, set to take effect in 2026, were projected to save Medicare enrollees around $1.5 billion in out-of-pocket expenses in their first year alone. The second round, now underway, is expected to have an even broader impact as it incorporates medications that have seen exponential growth in demand, such as the GLP-1 class used for diabetes and weight loss.
The Congressional Budget Office (CBO) anticipates that by 2027, the negotiated prices of Ozempic and Wegovy will drop substantially — cutting Medicare’s per-patient spending on these drugs by about one-third. The ripple effect could also pressure competing drugs, including Mounjaro and Zepbound, to reduce their prices, amplifying savings across the market.
For specialists such as Stacie Dusetzina, a health policy academic at Vanderbilt University, these occurrences demonstrate how structured discussions can instigate genuine market shifts. “We are all anticipating the formal announcement of the updated prices,” she stated. “It’s quite conceivable that the expectation of these discussions has already impacted other pricing choices.”
Political Discourses and Financial Circumstances
Despite the program’s potential, Trump’s administration has remained largely silent about it. The White House instead continues to highlight its voluntary agreements with pharmaceutical companies as evidence of its commitment to lowering costs. In a written statement, spokesperson Kush Desai argued that while Democrats “touted the Inflation Reduction Act,” it ultimately “increased Medicare premiums,” claiming that Trump’s direct engagement with drugmakers is producing “historic” results.
Health policy experts, however, advise against dismissing the Medicare negotiation process as ineffective. They point out that while voluntary agreements might attract notice, they cannot substitute for structured policy changes enshrined in legislation. “The Inflation Reduction Act’s negotiation initiative is not only operational but also growing,” stated Tricia Neuman, executive director of the Medicare policy program at KFF. “It’s intended to reduce the cost of many more medications over time.”
Experts also point out that pharmaceutical companies face strong incentives to cooperate with Medicare. Refusing to participate in negotiations could mean losing access to one of the largest and most lucrative prescription markets in the world — a move few drugmakers are willing to risk. Several companies have challenged the negotiation authority in court, but none have succeeded in halting the process.
Rome reiterated that the negotiation framework established by CMS is deliberate and resilient. “This process has been carefully structured and will continue year after year,” he said. “It’s unlikely that side agreements, even with major manufacturers, will disrupt it.”
A more extensive influence on the cost-effectiveness of healthcare
The discussion surrounding optimal strategies for lowering pharmaceutical expenses highlights a more fundamental inquiry into the trajectory of healthcare policy within the United States. Data from KFF indicates that one out of every five adults foregoes necessary prescriptions due to their expense, a clear illustration of the financial strain experienced by countless Americans. For senior citizens living on fixed incomes, the distinction between a temporary price cut and a lasting decrease in cost can dictate their ability to reliably obtain their essential medications.
By institutionalizing negotiations through Medicare, the Inflation Reduction Act seeks to create a predictable framework that steadily expands over time. Each new round adds more drugs to the list, gradually reshaping the economics of the pharmaceutical market. If successful, it could establish a long-term model for balancing innovation, affordability, and accountability.
Meanwhile, Trump’s ad hoc agreements underscore the challenges of balancing politics with policy. Voluntary deals may deliver quick headlines and selective savings, but without systemic oversight, their long-term benefits remain uncertain. Experts warn that relying solely on private agreements could leave gaps in affordability and undermine efforts to establish consistent nationwide standards for pricing.
As the nation awaits CMS’s release of the new negotiated prices later this month, the contrast between these two strategies has never been clearer. On one hand, Trump’s approach relies on negotiation through influence — emphasizing speed and visibility. On the other, the Medicare program operates through legislation and institutional authority, prioritizing stability and fairness over immediate results.
The results of these strategies could influence the trajectory of pharmaceutical policy for many years ahead. For countless Americans grappling with escalating drug expenses, the implications are profoundly significant.
Ultimately, both approaches embody contrasting viewpoints on the management of governance and market dynamics. Although informal agreements might provide immediate respite, formalized negotiations hold the potential for a more lasting impact — a fundamental change in how the nation perceives health, equity, and responsibility within its core frameworks.
